Announcements LOREM IPSUM

Nanite Announces Strategic Collaboration with SalioGen Therapeutics to Develop Non-Viral, Lung-Targeting Nanoparticle for Cystic Fibrosis Genetic Medicine

Boston, Mass.

Research collaboration will use Nanite’s SAYER™ platform and SalioGen’s novel Gene Coding™ technology to deliver CFTR gene directly to the lungs of people with CF

Boston, Mass., May, 29, 2024 –  Nanite, Inc. and SalioGen Therapeutics today announced a research collaboration that will utilize Nanite’s SAYER™ delivery platform to develop a lung-targeting polymer nanoparticle (PNP) designed to integrate the cystic fibrosis transmembrane conductance regulator (CFTR) gene directly into lung cells using SalioGen’s novel Gene Coding™ technology. Mutations in the CFTR gene cause cystic fibrosis (CF), a chronic and life-threatening condition that progressively damages the lungs, digestive system, and other organs.

Nanite’s proprietary SAYER platform combines AI-driven polymer design with multiplexed in vivo screening to develop best-in-class PNPs for tissue-specific delivery. SAYER has demonstrated strong efficiency and high specificity for targeting the lungs, potentially overcoming the limitations of viral vectors and lipid nanoparticles.

SalioGen’s Gene Coding technology uses a bioengineered transposase enzyme to deliver an optimized construct containing the entire gene of interest, regardless of size, to a precise location in the genome of target cells. In vitro experiments successfully demonstrated the ability to integrate the full-length CFTR gene into human lung cells.

Under the terms of the agreement, Nanite will design a resorbable polymer delivery vehicle for SalioGen’s Gene Coding technology. “Nanite’s relationship with SalioGen is consequential in discovering safe polymeric nanoparticles for a transformative treatment for CF,” notes Nanite co-founder and CEO Sean Kevlahan.”In addition to ongoing Nanite research supported by the the Cystic Fibrosis Foundation’s Path to a Cure, the SalioGen collaboration underscores the power of the SAYER platform’s capacity to design fit-for-purpose delivery vehicles.”

“We are excited to announce this collaboration with Nanite, as it represents an important step forward in our mission to accelerate the impact of genetic medicine for patients using our novel Gene Coding technology,” said Jason Cole, CEO of SalioGen Therapeutics. “By combining the innovative approaches of both companies, we hope to create a non-viral genetic medicine delivered directly to the lungs and provide the first permanent therapy for people living with CF, regardless of mutation.”

Nanite, Inc. is a non-viral gene delivery company developing programmable, tissue-specific polymer nanoparticles (PNPs) for a broad range of modalities and indications. Powered by our AI-driven platform, SAYER™, Nanite is building the next generation of non-viral delivery vehicles – programmable, targeted, and safe – for a new wave of genetic medicines. SAYER™ applies state-of-the-art machine learning-methods to combine high-throughput experimental and computational polymer chemistry to design fit-for-purpose delivery vehicles. Nanite is headquartered in Boston, MA. For more information, visit and follow Nanite on LinkedIn.

SalioGen Therapeutics is developing next-generation genetic medicines for patients using its novel Gene Coding™ technology. Gene Coding is a non-viral method of integrating large or multiple whole genes into the genome at precise locations without double-strand breaks or guide RNA. SalioGen’s lead programs focus on one-time treatments for Stargardt disease and cystic fibrosis. The company is also developing its Gene Coding technology for additional indications, such as other inherited retinal diseases, and to engineer CAR-T cells for cancer and autoimmune conditions. SalioGen is headquartered in Lexington, Massachusetts. For more information, visit and follow SalioGen on LinkedIn.

Media Contacts:
Mih-Ho Cha for Nanite, Inc.

Lori Rosen for SalioGen Therapeutics
LDR Communications

Investor Relations

Media Relations

Jason F. Cole

CEO & Chairman of the Board

Jason is a strategic biotechnology CEO and board member with over 20 years of experience working with public and private biotech companies focused on strategy, capital raising, business development, operations, and enabling teams.

Jason joined SalioGen from bluebird bio, where he served as Chief Strategy and Financial Officer, Chief Business Officer, and Chief Operating and Legal Officer, providing strategic, financial, operational, and legal oversight during key growth and transition periods. In these roles, bluebird bio scaled from 100 to 1,200 employees (U.S. & Europe), secured FDA approval of three first-of-their-kind gene and cell therapies (ZYNTEGLO, SKYSONA, ABECMA), and closed over $3.7 billion in financings and strategy-enabling business development transactions. Before bluebird bio, Jason held positions on the executive leadership teams of Zalicus and CombinatoRx, with responsibility across corporate development, strategic alliances, legal, IT, and facilities.

Jason earned a J.D. from Columbia University and an A.B. in Government from Dartmouth College.

Joseph J. Higgins, M.D.

Chief Innovation Officer, Co-Founder & Board Member

Joe is an executive leader, clinician, and scientist dedicated to advancing gene therapies for children and adults with genetic disorders involving the cardiovascular, ophthalmological, neurological, and immunological systems. His background spans pediatrics, child neurology, medical genetics, and molecular developmental neurobiology.

Earlier in his career, Joe worked on the Human Genome Project as the lead of the Human Genetic Initiative. His academic background includes positions as an instructor at Harvard Medical School, an Assistant Professor at George Washington University, an Associate Professor at SUNY Albany, and a Professor at Cornell University. As the Vice President of Clinical Development at uniQure, Joe led Phase 1/2 first-in-human gene therapy trials in Huntington’s disease.

Joe received his medical degree from New York University and graduated cum laude with a B.A. in Biology from Marist College. He is double-board certified in Pediatrics and Neurology with Special Qualification in Child Neurology. He is licensed to practice medicine in New York and Massachusetts.

Jeff Kopacz, M.S., J.D.

Senior Vice President, Intellectual Property & Contracts

Jeff has extensive intellectual property (IP) experience, including building and defending IP protection for platform-based technologies and FDA-approved therapeutics.

Previously, Jeff served as Vice President of Intellectual Property at Omega Therapeutics, leading IP and contract activities related to their genomic control technology. Before Omega, Jeff worked at Alnylam Pharmaceuticals for ten years, most recently as Senior Director, Senior Intellectual Property counsel.

Earlier, Jeff was an attorney at Edwards Angell Palmer & Dodge LLP (now Locke Lord LLP) Jeff began his biopharma career at Millennium Pharmaceuticals (now Takeda Pharmaceuticals).

Jeff received his undergraduate degree in microbiology from the University of Massachusetts at Amherst, his graduate degree in molecular microbiology and immunology from Johns Hopkins University, and a law degree from Suffolk University Law School.

Kate Lewis

Vice President, Portfolio and Program Management

Kate is a biotech leader with 20 years of experience in life sciences and drug development, including extensive work in gene therapy. Her focus is portfolio management, strategic planning, communications, and team leadership.

Prior to SalioGen, Kate served as Vice President, Program Lead and Head of Program Management at Syndax Pharmaceuticals and Freeline Therapeutics. Before that, Kate spent nearly seven years at bluebird bio in roles in Medical Affairs and Program Leadership.

Kate holds a B.A. from Pomona College and an M.A. from the University of Iowa, both in English literature.

Will McGowan

Executive Director, Finance & FP&A

Will is a financial leader with over 15 years of experience working in both public and private biotech companies at all stages of development, from discovery through commercialization.

Will most recently was the Senior Director of FP&A for Allena Pharmaceuticals. Before that role, He spent five years as the Senior Director of Finance and Controller for Navitor Pharmaceuticals and nine years at AMAG Pharmaceuticals in various roles, including Controller and Director of FP&A.

Will holds an MBA from Quinnipiac University and a Bachelor of Science in Finance and Accounting from the Darla Moore School of Business at the University of South Carolina.

Jill Murray

Vice President, Human Resources

Jill is a senior human resources professional with 20+ years of progressive experience in the biotech industry. Her focus is organizational design, employee development, employee relations, leadership coaching, change management, compensation, benefits administration, and legal compliance.

Jill began her career at ImmunoGen, where she covered all facets of Human Resources and Talent Management during her 14-year tenure. After that, Jill joined Sarepta Therapeutics, where she was responsible for establishing and building the HR Business Partnering function, followed by Rubius Therapeutics where she served as Head of Human Resources.

Jill holds a bachelor’s degree in art and psychology from Carnegie Mellon University and is a certified Executive Coach.

Sandeep Nema, Ph.D.

Senior Vice President, Technical Operations

Sandeep has extensive developmental experience in bringing candidates to clinic that span various modalities, including gene therapy, ADCs, mAbs, vaccines, oligonucleotides, bi/tri-specific, and CART.

Before SalioGen, Sandeep worked for 24 years at Pfizer. Recently, his team successfully brought Pfizer’s COVID-19 LNP-mRNA vaccine to the clinic and achieved emergency use authorization. In his last role as Executive Director, Biotherapeutics Pharmaceutical Sciences, Global Biologics, Sandeep was responsible for all pre-proof-of-concept biologics projects, approximately 50 in total, from discovery up to Phase 3 start. Before that, Sandeep established the Protein Pharmaceutical R&D group at Pfizer, which included Formulation, Microbiology, and Stability functions. He is also an adjunct Professor at the University of Tennessee.

Sandeep earned his Ph.D. in Pharmaceuticals from the University of Tennessee Health Science Center and his Bachelor of Pharmacy from Banaras Hindu University. He is also a Certified Regulatory Affairs Professional.

Joe Senn, Ph.D.

Senior Vice President, Head of R&D

Joe is an R&D leader with experience in nearly all therapeutic modalities, including small molecules, biologics, antisense, gene editing, and mRNA therapeutics. He most recently served as the Vice President of Nonclinical Development at Moderna Therapeutics, where he and his team were responsible for progressing over 40 candidates into the clinic. Before Moderna, Joe served as Site Head for Drug Safety at Takeda Pharmaceuticals, overseeing the development of all immunology products across the portfolio.

Joe earned his Ph.D. in Pharmacology and Physiology from the University of Rochester School of Medicine and Dentistry and his B.S. from Niagara University.